The Invesco Perpetual Income Fund aims to achieve a reasonable level of income, together with capital growth. The fund intends to invest primarily in companies listed in the UK, with the balance invested internationally.
Name | % Net Assets |
---|---|
GlaxoSmithKline | 7.1% |
AstraZeneca | 6.7% |
GlaxoSmithKline | 6.7% |
Reynolds American | 5.5% |
Vodafone | 5.0% |
Reynolds American | 4.9% |
Tesco | 4.6% |
BP | 4.3% |
National Grid | 4.3% |
Imperial Tobacco | 4.0% |
Key | % Net Assets |
---|---|
GlaxoSmithKline | 7.1% |
AstraZeneca | 6.7% |
GlaxoSmithKline | 6.7% |
Reynolds American | 5.5% |
Other | 74% |
Date | 21-Nov-2024 |
---|---|
NAV | 187.09p |
Currency | GBP |
Change | 0.24p |
% | 0.13% |
YTD change | 13.20p |
YTD % | 7.59% |
Fund Inception | 16/06/1979 |
---|---|
Fund Manager | Neil Woodford |
TER | 1.19 (31-Dec-2013) |
Minimum Investment | |
---|---|
Initial | £500 |
Additional | n/a |
Savings | £20 |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.16% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research